187 related articles for article (PubMed ID: 36547753)
1. Identification of potential inhibitors of Mycobacterium tuberculosis shikimate kinase: molecular docking, in silico toxicity and in vitro experiments.
Freitas de Freitas T; Roth CD; Abbadi BL; Hopf FSM; Perelló MA; de Matos Czeczot A; de Souza EV; Borsoi AF; Machado P; Bizarro CV; Basso LA; Timmers LFSM
J Comput Aided Mol Des; 2023 Mar; 37(3):117-128. PubMed ID: 36547753
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel antimicrobial compounds targeting Mycobacterium tuberculosis shikimate kinase using in silico hierarchical structure-based drug screening.
Kawamoto S; Hori C; Taniguchi H; Okubo S; Aoki S
Tuberculosis (Edinb); 2023 Jul; 141():102362. PubMed ID: 37311288
[TBL] [Abstract][Full Text] [Related]
3. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
Rajput VS; Mehra R; Kumar S; Nargotra A; Singh PP; Khan IA
Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
[TBL] [Abstract][Full Text] [Related]
4. Benzothiazole Derivative as a Novel Mycobacterium tuberculosis Shikimate Kinase Inhibitor: Identification and Elucidation of Its Allosteric Mode of Inhibition.
Mehra R; Rajput VS; Gupta M; Chib R; Kumar A; Wazir P; Khan IA; Nargotra A
J Chem Inf Model; 2016 May; 56(5):930-40. PubMed ID: 27149193
[TBL] [Abstract][Full Text] [Related]
5. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
Simithy J; Reeve N; Hobrath JV; Reynolds RC; Calderón AI
Tuberculosis (Edinb); 2014 Mar; 94(2):152-8. PubMed ID: 24429106
[TBL] [Abstract][Full Text] [Related]
6. Toxicological Profiling of Potential Shikimate Kinase Inhibitors Against
Jhangiani A; Panda V; Sukheja A; Thomas S; Dusseja P; Pandya S; Chintakrindi A
Altern Lab Anim; 2024 Jan; 52(1):10-27. PubMed ID: 38095084
[TBL] [Abstract][Full Text] [Related]
7. Shikimate Kinase Inhibitors: An Update on Promising Strategy against
Rajput VS; Runthala A; Khan IA
Curr Drug Targets; 2023; 24(5):388-405. PubMed ID: 36752299
[TBL] [Abstract][Full Text] [Related]
8.
Qureshi KA; Azam F; Fatmi MQ; Imtiaz M; Prajapati DK; Rai PK; Jaremko M; Emwas AH; Elhassan GO
PeerJ; 2023; 11():e14502. PubMed ID: 36935926
[TBL] [Abstract][Full Text] [Related]
9. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
10. Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials.
Gordon S; Simithy J; Goodwin DC; Calderón AI
Perspect Medicin Chem; 2015; 7():9-20. PubMed ID: 25861218
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
12. Structure-based Discovery of Narirutin as a Shikimate kinase Inhibitor with Anti-tubercular Potency.
Sahu PK; Mohapatra PK; Rajani DP; Raval MK
Curr Comput Aided Drug Des; 2020; 16(5):523-529. PubMed ID: 31654517
[TBL] [Abstract][Full Text] [Related]
13. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone.
Simithy J; Fuanta NR; Hobrath JV; Kochanowska-Karamyan A; Hamann MT; Goodwin DC; Calderón AI
Biochim Biophys Acta Proteins Proteom; 2018; 1866(5-6):731-739. PubMed ID: 29654976
[TBL] [Abstract][Full Text] [Related]
15. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling and docking studies of O-succinylbenzoate synthase of M. tuberculosis--a potential target for antituberculosis drug design.
Pulaganti M; Banaganapalli B; Mulakayala C; Chitta SK; C M A
Appl Biochem Biotechnol; 2014 Feb; 172(3):1407-32. PubMed ID: 24203275
[TBL] [Abstract][Full Text] [Related]
17. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
[TBL] [Abstract][Full Text] [Related]
18. Identification of new potential Mycobacterium tuberculosis shikimate kinase inhibitors through molecular docking simulations.
Vianna CP; de Azevedo WF
J Mol Model; 2012 Feb; 18(2):755-64. PubMed ID: 21594693
[TBL] [Abstract][Full Text] [Related]
19. In silico docking and molecular dynamics simulation of 3-dehydroquinate synthase (DHQS) from Mycobacterium tuberculosis.
Isa MA; Majumdhar RS; Haider S
J Mol Model; 2018 May; 24(6):132. PubMed ID: 29752576
[TBL] [Abstract][Full Text] [Related]
20. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
